Do rheumatic diseases, long‐term glucocorticoids, and immunosuppressant treatment, and vaccination impact the COVID‐19 severity? Insight from a retrospective cohort study DOI
Yi Ma,

Chang Wei,

Zixi Yi

et al.

International Journal of Rheumatic Diseases, Journal Year: 2024, Volume and Issue: 27(7)

Published: July 1, 2024

Abstract Objectives The impact of rheumatic diseases, long‐term medication, and vaccination on COVID‐19 severity remain insufficiently understood, hindering effective patient management. This study aims to investigate factors influencing in Chinese patients provide real‐world evidence for care. Methods We conducted a retrospective observational consisting two cohorts, followed by nested case–control analysis. outpatient cohort included non‐severe patients, while the inpatient consecutive severe inpatients. Additionally, from both cohorts were study. Clinical information was obtained electronic medical records surveys. Results A total 749 outpatients 167 inpatients enrolled. In cohort, diseases identified as risk factor dyspnea (No disease: OR = 0.577, 95% CI 0.396–0.841, p .004), but not mortality, length hospitalization, or hospitalization costs cohort. Long‐term glucocorticoids use an independent (OR 1.814, 1.235–2.663, .002), immunosuppressant treatment showed no association. Vaccination protective against due with 0.031, 0.007–0.136, < .001), whereas Conclusions Rheumatic are significant population, emphasizing effects vaccines is crucial. investigation provides preliminary support concept that therapy does necessarily require additional prescription adjustments.

Language: Английский

Leveraging near-real-time patient and population data to incorporate fluctuating risk of severe COVID-19: development and prospective validation of a personalised risk prediction tool DOI Creative Commons
Kaitlin N. Swinnerton, Nathanael R. Fillmore,

Austin D Vo

et al.

EClinicalMedicine, Journal Year: 2025, Volume and Issue: 81, P. 103114 - 103114

Published: Feb. 21, 2025

Language: Английский

Citations

0
Pulmonary aspergillosis in US Veterans with COVID-19: a nationwide, retrospective cohort study DOI Creative Commons
Kaitlin N. Swinnerton, Nathanael R. Fillmore, Ikwo Oboho

et al.

Antimicrobial Stewardship & Healthcare Epidemiology, Journal Year: 2025, Volume and Issue: 5(1)

Published: Jan. 1, 2025

Abstract Background: COVID-associated pulmonary aspergillosis (CAPA) was described early in the pandemic as a complication of SARS-CoV-2. Data about incidence and characteristics affected patients after mid-2021 are limited. Methods: A retrospective, nationwide cohort US Veterans with SARS-CoV-2 from 1/1/2020 to 2/7/2024 created. Potential cases ≤12 weeks test were flagged electronically (based on testing results indicative invasive fungal infection, antifungal therapy, and/or ICD-10 codes), followed by manual review establish clinical diagnosis aspergillosis. Incidence rates calculated per 10,000 cases. Selected included age >70, receipt immune-compromising drugs, hematologic malignancy, chronic respiratory disease, vaccination status, vaccine era. Multivariate logistic regression used estimate independent effects these variables via adjusted odds ratios (aOR). Results: Among 674,343 SARS-CoV-2, 165 for review. Of these, 66 judged be proportions ranged 0.30/10,000 among zero risk factors 34/10,000 those ≥3 factors; similar pre- post-vaccination eras. The 90-day mortality 50%. In multivariate analysis, immune suppression (aOR 6.47, CI 3.84–10.92), disease 3.57, 2.10–6.14), >70 2.78, 1.64–4.80) associated Conclusions: Patients underlying continue at some despite immunization. Risk without or preexisting lung is very low.

Language: Английский

Citations

0
Severe COVID‐19 in solid organ transplant recipients in the post‐vaccination era: Persistence in the burden of disease and in disparities of care DOI Open Access
Abhay Dhand, Kenji Okumura, Seigo Nishida

et al.

Transplant Infectious Disease, Journal Year: 2023, Volume and Issue: unknown

Published: Nov. 27, 2023

The authors declare no conflict of interest. Data sharing not applicable to this article as datasets were generated or analyzed during the current study.

Language: Английский

Citations

2
Rheumatoid arthritis and COVID-19 outcomes: a systematic review and Meta-analysis DOI Creative Commons

Liang Jin,

Jen Ling Gan, Xuewei Li

et al.

BMC Rheumatology, Journal Year: 2024, Volume and Issue: 8(1)

Published: Nov. 12, 2024

This study aimed to conduct a comprehensive systematic literature review and meta-analysis assess the risk outcomes of coronavirus disease 2019 (COVID-19) in patients with rheumatoid arthritis. A search was performed across four electronic databases. The quality studies assessed using Newcastle‒Ottawa assessment scale Joanna Briggs Institute critical appraisal checklist. Statistical analyses were conducted STATA 14 software. total 62 included analysis. First, revealed following prevalence rates among arthritis patients: COVID-19, 11%; severe 18%; COVID-19-related hospitalization, 29%; admission intensive care unit (ICU) due 10%; death from 8%. Second, associated an increased COVID-19 infection (OR 1.045(0.969–1.122), p = 0.006), hospitalization 1.319(1.055–1.584), ICU 1.498(1.145–1.850), 0.002), 1.377(1.168–1.587), 0.001). Third, no statistically significant association found between 1.354(1.002–1.706), 0.135). Rheumatoid have significantly greater infection, admission, than individuals without However, did not show COVID-19. These findings underscore need for tailored management strategies vigilant monitoring patients. has been registered on PROSPERO [ https://www.crd.york.ac.uk/PROSPERO/ ], registration number is CRD42024528119.

Language: Английский

Citations

0
Do rheumatic diseases, long‐term glucocorticoids, and immunosuppressant treatment, and vaccination impact the COVID‐19 severity? Insight from a retrospective cohort study DOI
Yi Ma,

Chang Wei,

Zixi Yi

et al.

International Journal of Rheumatic Diseases, Journal Year: 2024, Volume and Issue: 27(7)

Published: July 1, 2024

Abstract Objectives The impact of rheumatic diseases, long‐term medication, and vaccination on COVID‐19 severity remain insufficiently understood, hindering effective patient management. This study aims to investigate factors influencing in Chinese patients provide real‐world evidence for care. Methods We conducted a retrospective observational consisting two cohorts, followed by nested case–control analysis. outpatient cohort included non‐severe patients, while the inpatient consecutive severe inpatients. Additionally, from both cohorts were study. Clinical information was obtained electronic medical records surveys. Results A total 749 outpatients 167 inpatients enrolled. In cohort, diseases identified as risk factor dyspnea (No disease: OR = 0.577, 95% CI 0.396–0.841, p .004), but not mortality, length hospitalization, or hospitalization costs cohort. Long‐term glucocorticoids use an independent (OR 1.814, 1.235–2.663, .002), immunosuppressant treatment showed no association. Vaccination protective against due with 0.031, 0.007–0.136, < .001), whereas Conclusions Rheumatic are significant population, emphasizing effects vaccines is crucial. investigation provides preliminary support concept that therapy does necessarily require additional prescription adjustments.

Language: Английский

Citations

0